🟢 Sanofi is trading 4.4% up in pre-market after beating Q3 estimates and upgrading 2026 outlook

Sanofi is trading at $45.03, up +4.41%, after Q3 business EPS topped analyst estimates and the company raised its 2026 outlook.

• Q3 sales grew 14.3% at constant exchange rates; business EPS was €3.55.
• Dupixent sales rose 34.8% to €5.7 billion.
• The 2026 outlook now calls for low-teens sales growth and mid-teens business EPS growth at constant exchange rates.